Skip to main content
Premium Trial:

Request an Annual Quote

EGEN microRNA Inhibitor Shows Promise in Preclinical Testing


EGEN announced this week that its microRNA inhibitor-based treatment for pulmonary arterial hypertension was able to reverse the pulmonary hypertension associated with advanced stages of the disease and restore cardiovascular function in rat models.

According to the company, the drug targets miR-145, which has been linked to vascular remodeling in PAH, and is delivered with a propriatry mPEG nanoparticle that is administered directly to the lung.

EGEN is also developing RNAi-based drugs with a focus on cancer (GSN 8/5/2010).